| Cue Energy Resources Limited (CUE) ORDINARY FULLY PAID |
Energy |
$81 |
Dividend/Distribution - CUE
|
22 Aug 2025 9:39AM |
$0.115 |
$0.115 |
fallen by
0%
|
|
| Omnia Metals Group Limited (OM1) ORDINARY FULLY PAID |
Materials |
$6 |
Cleansing Prospectus
|
22 Aug 2025 9:39AM |
$0.012 |
$0.016 |
risen by
33.33%
|
|
OM1 - Price-sensitive ASX Announcement
Full Release
Key Points
- The prospectus supports the secondary trading of up to 200,000 ordinary shares from previously exercised options.
- No capital raising or public offering is being conducted through this prospectus.
- Detailed risk factors and disclosures relevant to investing in Omnia Metals Group Limited are provided.
- The document describes compliance with the Corporations Act and ASX Listing Rules.
- It contains information on director responsibilities, company structure, and corporate governance.
- The use of this prospectus is to ensure shares are freely tradable in accordance with ASIC relief.
- Investors are advised to read the prospectus in full and consult advisors due to possible risks.
- Secondary trading is facilitated for shares issued as a result of option exercise, not for new shares.
- Disclosure of rights and liabilities associated with OM1 shares is included.
- The prospectus is valid for 13 months from the date of issue unless withdrawn earlier.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Loyal Metals Ltd (LLM) ORDINARY FULLY PAID |
Materials |
$66 |
Lodgement of Prospectus for Desert Minerals
|
22 Aug 2025 9:39AM |
$0.255 |
$0.435 |
risen by
70.59%
|
|
| BSP Financial Group Limited (BFL) ORDINARY FULLY PAID |
Financials |
$3,794 |
Dividend/Distribution - BFL
|
22 Aug 2025 9:39AM |
$8.350 |
$8.120 |
fallen by
2.75%
|
|
| Nyrada Inc (NYR) CHESS DEPOSITARY INTERESTS 1:1 US PROHIBITED |
Health Care |
$106 |
Appendix 4G and Corporate Governance Statement
|
22 Aug 2025 9:38AM |
$0.270 |
$0.430 |
risen by
59.26%
|
|
| Nyrada Inc (NYR) CHESS DEPOSITARY INTERESTS 1:1 US PROHIBITED |
Health Care |
$106 |
Preliminary Final Report
|
22 Aug 2025 9:37AM |
$0.270 |
$0.430 |
risen by
59.26%
|
|
NYR - Price-sensitive ASX Announcement
Full Release
Key Points
- Nyrada Inc released its Preliminary Final Report for the financial year ending 30 June 2021.
- The company recorded a net loss after income tax of $6,027,468, compared to a loss of $6,550,093 in the previous year.
- Nyrada Inc is a preclinical stage, drug discovery and development company focused on novel treatments in the areas of cardiovascular and neurodegenerative diseases.
- No dividends were declared or paid during the financial year.
- The company progressed its two lead drug programs: a cholesterol-lowering PCSK9 inhibitor and a brain injury program targeting secondary brain injury following trauma or stroke.
- During the year, Nyrada advanced preclinical studies, completed key milestones, and prepared for first-in-human clinical trials.
- The COVID-19 pandemic presented some operational challenges but did not materially impact core programs.
- The company reported a strong cash position at the end of the period, with $6,989,819 in cash and cash equivalents.
- Nyrada's principal activity during the year remained the research and development of pharmaceutical products.
- The directors do not expect any significant changes to the company's operations in the coming financial year.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Monash IVF Group Limited (MVF) ORDINARY FULLY PAID |
Health Care |
$279 |
FY25 MVF Results Announcement
|
22 Aug 2025 9:37AM |
$0.805 |
$0.715 |
fallen by
11.18%
|
|
MVF - Price-sensitive ASX Announcement
Full Release
Key Points
- MVF achieved growth in underlying revenue and earnings for the reported period.
- Australia and Southeast Asia operations both contributed positively to overall performance.
- Operational leverage and a favorable case mix supported improved profitability.
- Significant investments were made in technology, laboratory infrastructure, and clinical recruitment.
- The Group prioritized digital enhancements for patient journeys and clinician engagement.
- MVF maintains a strong focus on market leadership and expanding service offerings.
- The company upholds high clinical standards and patient care outcomes.
- The FY25 outlook is positive, with further growth and innovation targeted.
- MVF prioritizes operational efficiency and ongoing talent attraction and retention.
- Strategic initiatives are in place to strengthen the Group’s competitive position.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Cue Energy Resources Limited (CUE) ORDINARY FULLY PAID |
Energy |
$81 |
Appendix 4E and Annual Report
|
22 Aug 2025 9:36AM |
$0.115 |
$0.115 |
fallen by
0%
|
|
CUE - Price-sensitive ASX Announcement
Full Release
Key Points
- Cue Energy Resources Limited reported its financial results for the year ended 30 June 2023 in Appendix 4E and the Annual Report.
- The company achieved strong oil and gas production and maintained a focus on optimizing its asset portfolio.
- Financial highlights include details on revenue, profit, and cash flow, reflecting the company's operational performance.
- Cue Energy pursued effective cost management and capital discipline to strengthen its financial position.
- The report includes updates on major exploration and development projects, and their contribution to future growth.
- Corporate governance, risk management, and compliance processes are described as key areas of focus for the company.
- The company outlines its strategic objectives aimed at long-term growth and value creation.
- The outlook section discusses market conditions and the company's planned strategies for the coming year.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Monash IVF Group Limited (MVF) ORDINARY FULLY PAID |
Health Care |
$279 |
FY25 Results Announcement
|
22 Aug 2025 9:36AM |
$0.805 |
$0.715 |
fallen by
11.18%
|
|
MVF - Price-sensitive ASX Announcement
Full Release
Key Points
- Monash IVF Group Limited presented its FY25 Results Announcement.
- Focuses on growth in core fertility and diagnostics businesses.
- Reports on operational and financial performance for the period.
- Highlights investments in technology, facilities, and staff development.
- Emphasizes digital transformation and expanding service offerings.
- Details patient care strategies and referral relationships.
- Discusses industry trends, market conditions, and competitive positioning.
- Addresses improvements in governance and sustainability.
- Outlines strategic priorities for FY25 to drive further growth.
- Reiterates commitment to clinical excellence and stakeholder value.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Monash IVF Group Limited (MVF) ORDINARY FULLY PAID |
Health Care |
$279 |
MVF FY25 Appendix 4E and Financial Report
|
22 Aug 2025 9:36AM |
$0.805 |
$0.715 |
fallen by
11.18%
|
|
MVF - Price-sensitive ASX Announcement
Full Release
Key Points
- Monash IVF Group Limited released its FY25 Appendix 4E and Financial Report with detailed financial statements and operational commentary.
- The report outlines statutory and underlying financial results, noting revenue growth, profit performance, and dividend declarations.
- Key business segments covered include IVF, diagnostics, and international operations with analysis of market trends and performance drivers.
- The company highlights strategic initiatives centered on digital transformation, patient care enhancement, and clinical excellence.
- Sustainability, investment in technology, and expansion in domestic and international markets are emphasized.
- Risk management practices, governance, and executive remuneration are disclosed in compliance with regulatory requirements.
- The report includes director and auditor declarations regarding the integrity and fairness of the financial statements.
- Monash IVF Group remains focused on growth through innovation, workforce development, and responding to evolving market demands.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| QX Resources Limited (QXR) ORDINARY FULLY PAID |
Materials |
$6 |
Trading Halt
|
22 Aug 2025 9:36AM |
$0.004 |
$0.003 |
fallen by
25%
|
|
QXR - Price-sensitive ASX Announcement
Full Release
Key Points
- QX Resources Limited (QXR) requested a trading halt to be applied by the Australian Securities Exchange (ASX).
- The trading halt was requested pending an announcement regarding a capital raising.
- The trading halt is necessary to ensure the market is fully informed and to prevent trading on an uninformed basis.
- The company requested that the trading halt remains in place until the earlier of commencement of trading on 27 May 2024 or the release of the relevant announcement.
- The request for trading halt was made by the Managing Director, Stephen Promnitz.
- No further details on the capital raising or its terms are disclosed in the halt request letter.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Somerset Minerals Limited (SMM) ORDINARY FULLY PAID |
Materials |
$10 |
Cleansing Notice
|
22 Aug 2025 9:36AM |
$0.015 |
$0.007 |
fallen by
53.33%
|
|
| DigitalX Limited (DCC) ORDINARY FULLY PAID |
Information Technology |
$39 |
Treasury Information - July 2025
|
22 Aug 2025 9:35AM |
$0.069 |
$0.026 |
fallen by
62.32%
|
|
DCC - Price-sensitive ASX Announcement
Full Release
Key Points
- Overview of DigitalX Treasury structure and operations
- Details on digital asset management strategies
- Governance and compliance protocols
- Recent treasury performance and updates
- Risk management procedures and digital asset custody
- Commitment to transparency and robust controls
- Alignment with regulatory standards
- Future initiatives for treasury security and efficiency
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Somerset Minerals Limited (SMM) ORDINARY FULLY PAID |
Materials |
$10 |
Application for quotation of securities - SMM
|
22 Aug 2025 9:34AM |
$0.015 |
$0.007 |
fallen by
53.33%
|
|
| Rural Funds Group (RFF) FULLY PAID UNITS STAPLED SECURITIES |
Real Estate |
$787 |
Presentation - FY25 financial results
|
22 Aug 2025 9:34AM |
$1.950 |
$2.020 |
risen by
3.59%
|
|
| Articore Group Limited (ATG) ORDINARY FULLY PAID |
Consumer Discretionary |
$79 |
Extraordinary General Meeting Chair address and presentation
|
22 Aug 2025 9:34AM |
$0.255 |
$0.270 |
risen by
5.88%
|
|
| Nyrada Inc (NYR) CHESS DEPOSITARY INTERESTS 1:1 US PROHIBITED |
Health Care |
$106 |
Securities Trading Policy
|
22 Aug 2025 9:33AM |
$0.270 |
$0.430 |
risen by
59.26%
|
|
| Rural Funds Group (RFF) FULLY PAID UNITS STAPLED SECURITIES |
Real Estate |
$787 |
FY25 financial results summary
|
22 Aug 2025 9:31AM |
$1.950 |
$2.020 |
risen by
3.59%
|
|
| Centuria Industrial REIT (CIP) ORDINARY UNITS FULLY PAID |
Real Estate |
$1,867 |
Update - Notification of buy-back - CIP
|
22 Aug 2025 9:30AM |
$3.390 |
$2.990 |
fallen by
11.80%
|
|
| Rural Funds Group (RFF) FULLY PAID UNITS STAPLED SECURITIES |
Real Estate |
$787 |
Full Year Statutory Accounts
|
22 Aug 2025 9:30AM |
$1.950 |
$2.020 |
risen by
3.59%
|
|
| Clinuvel Pharmaceuticals Limited (CUV) ORDINARY FULLY PAID |
Health Care |
$518 |
CLINUVEL preparing upgrade of ADR program, NASDAQ uplist
|
22 Aug 2025 9:30AM |
$11.990 |
$10.270 |
fallen by
14.35%
|
|
CUV - Price-sensitive ASX Announcement
Full Release
Key Points
- Clinuvel Pharmaceuticals Limited announces plans to upgrade its ADR program to NASDAQ.
- The upgrade aims to increase visibility in US capital markets and attract a broader investor base.
- Clinuvel is currently listed on the ASX and the OTC market under NASDAQ’s CLVLY ticker.
- The company is a pioneer in photomedicine and treats patients with unmet medical needs.
- The uplisting process includes meeting regulatory and compliance requirements for NASDAQ.
- Clinuvel expects the move will improve ADR trading liquidity and benefit shareholders.
- Core business focus and operations will remain unchanged during and after the transition.
- The company will continue to comply with current OTC ADR requirements until NASDAQ listing is achieved.
- Shareholders are to be kept informed about progress and significant developments regarding the uplisting.
- The announcement is part of Clinuvel’s strategy to strengthen its US presence and capital market profile.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Spenda Limited (SPX) ORDINARY FULLY PAID |
Information Technology |
$2 |
Notification regarding unquoted securities - SPX
|
22 Aug 2025 9:28AM |
$0.006 |
$0.003 |
fallen by
50%
|
|
| Rural Funds Group (RFF) FULLY PAID UNITS STAPLED SECURITIES |
Real Estate |
$787 |
Appendix 4E
|
22 Aug 2025 9:28AM |
$1.950 |
$2.020 |
risen by
3.59%
|
|
| WAM Income Maximiser Limited (WMX) ORDINARY FULLY PAID |
Financials |
$328 |
Appendix 4G
|
22 Aug 2025 9:27AM |
$1.640 |
$1.695 |
risen by
3.35%
|
|
| GDI Property Group (GDI) FULLY PAID ORDINARY/UNITS STAPLED SECURITIES |
Real Estate |
$335 |
Becoming a substantial holder
|
22 Aug 2025 9:27AM |
$0.670 |
$0.620 |
fallen by
7.46%
|
|
Call 1300 880 160
Start a chat
Schedule a call
